Tiziana Life Sciences Interview to Air on Bloomberg Television U.S. on the RedChip Money Report NEW YORK & LONDON

Tiziana Life Sciences Interview to Air on

Bloomberg Television U.S. on the RedChip Money Report

NEW YORK & LONDON, May 7, 2021 - Tiziana

Life Sciences plc (NASDAQ: TLSA, LSE: TILS), a biotechnology

company focused on innovative therapeutics for oncology, inflammation and infectious diseases, today announced an interview with CEO and

CSO Dr. Kunwar Shailubhai will air on The RedChip Money Report on the Bloomberg Network in the U.S. on Saturday, May 8 at 7 p.m. local

time. The RedChip Money Report airs on Bloomberg Television U.S. on Saturdays at 7 p.m. local time in approximately 73M homes.

To view the interview segment, please visit:

"The RedChip Money Report" delivers

insightful commentary on small-cap investing, interviews with Wall Street analysts, financial book reviews, as well as featured interviews

with executives of public companies.

About Tiziana Life Sciences

Tiziana Life Sciences plc (TLSA) is a UK biotechnology

company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition

to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody

in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases,

such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis

and rheumatoid arthritis, where modulation of a T-cell response is desirable. The Company is accelerating development of anti-Interleukin

6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19

Forward-Looking Statements

Certain statements made in this announcement are forward-looking

statements. These forward-looking statements are not historical facts but rather are based on the Company's current expectations, estimates,

and projections about its industry; its beliefs; and assumptions. Words such as 'anticipates,' 'expects,' 'intends,' 'plans,' 'believes,'

'seeks,' 'estimates,' and similar expressions are intended to identify forward-looking statements. These statements are not guarantees

of future performance and are subject to known and unknown risks, uncertainties, and other factors, some of which are beyond the Company's

control, are difficult to predict, and could cause actual results to differ materially from those expressed or forecasted in the forward-looking

statements. The Company cautions security holders and prospective security holders not to place undue reliance on these forward-looking

statements, which reflect the view of the Company only as of the date of this announcement. The forward-looking statements made in this

announcement relate only to events as of the date on which the statements are made. The Company will not undertake any obligation to release

publicly any revisions or updates to these forward-looking statements to reflect events, circumstances, or unanticipated events occurring

after the date of this announcement except as required by law or by any appropriate regulatory authority.

For further enquiries:

Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder

RedChip Companies Inc.

Source: Tiziana Life Sciences